Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3XR
|
|||
| Former ID |
DIB008898
|
|||
| Drug Name |
Tefibazumab
|
|||
| Synonyms |
Aurexis; Monoclonal antibodies (S aureus infections), Inhibitex; Monoclonal antibodies (Staphylococcus aureus infections), Inhibitex; MAb 12-9 (S aureus infections), Inhibitex; MAb 12-9 (Staphylococcus aureus infections), Inhibitex; SA-mAb (S aureus infections), Inhibitex; SA-mAb (Staphylococcus aureus infections), Inhibitex
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 2 | [1] | |
| Company |
Inhibitex
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00198289) Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.